toripalimab   Click here for help

GtoPdb Ligand ID: 12989

Synonyms: JS-001 | JS001 | Loqtorzi® | toripalimab-tpzi
Approved drug Immunopharmacology Ligand
toripalimab is an approved drug (FDA (2023))
Compound class: Antibody
Comment: Toripalimab (JS001) is an anti-programmed cell death protein-1 (PD-1) immuno-oncology biologic [3]. It blocks the inhibitory immune checkpoint interaction between PD-1 and its ligands and reinstates a cytotoxic T cell response against tumour cells.
Click here for help
Bioactivity Comments
JS001 blocks binding of PD-1 to its ligands PD-L1 and PD-L2 with similar potencies (IC50 ~3.0 nM) [3]. It does not bind to PD-1 antigens on rodent peripheral blood mononuclear cells.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Hs Antibody Binding 8.7 pKd - 3
pKd 8.7 (Kd 2.1x10-9 M) [3]
Description: Binding affinity for PD-1 on human CD8+ T cells
programmed cell death 1 (CD279) Monkey Antibody Binding 8.9 pKi - 3
pKi 8.9 (Ki 1.2x10-9 M) [3]
Description: Binding affinity for PD-1 on cynomolgus monkey CD8+ T cells
programmed cell death 1 (CD279) Hs Antibody Binding 7.7 pEC50 - 3
pEC50 7.7 (EC50 2.1x10-8 M) [3]
Description: Measuring displacement of biotin-PD-L1 from 293F cells expressing hPD-1